arrow
F

Francesco Patti

University of Catania
H指数:70
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

How patients with neuromyelitis optica spectrum disease accumulate disability

视神经脊髓炎谱系疾病患者如何累积残疾

2026-10-080
PRE
Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study

在记录有化疗暴露的人群中,癌症诊断后的多发性硬化结局:一项真实世界MSBase研究

2026-08-020
PRE
Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

在复发缓解型多发性硬化中,针对临床静息期MRI病灶的治疗升级

Brain
IF11.7
2026-07-240
OAAI
Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study)

评估接受不同治疗方案序列治疗的视神经脊髓炎患者队列中长期严重不良事件风险的概况:意大利视神经脊髓炎及相关疾病登记研究(I-MS&RD)(ProSA研究)结果

2026-07-040
PRE
A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis

儿科起病多发性硬化中度疗效治疗后早期强化治疗的预测工具

2026-06-010
PRE
Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study)

利妥昔单抗在高活性疾病修饰疗法治疗后的复发型多发性硬化中的有效性(RENEGADE研究)

2025-12-240
OAAI
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry

多发性硬化疾病 modifying therapies 之间水平切换的实效性:MSBase 注册数据库的回顾性分析

2025-12-230
PRE
Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study (vol 12, e200450, 2025)

Bennett JL,Fujihara K,Saiz A,Traboulsee AL,Greenberg BM,Weinshenker BG,等。来自SAkuraMoon开放标签扩展研究的视神经脊髓炎谱系障碍患者中萨他利珠单抗的长期疗效与安全性。Neurology® Neuroimmunology Neuroinflamm.(2025)12:e200450。doi:10.1212/NXI.0000000000200494。

2025-11-010
PRE
Disease course after pregnancy in women with progressive multiple sclerosis symptoms

妊娠后进展性多发性硬化症状女性的疾病病程

2025-09-200
OA
Persistent progression independent of relapse activity in multiple sclerosis

多发性硬化中与复发活动无关的持续性进展

2025-08-210
OAAI
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

造血干细胞移植与免疫重建疗法在复发型多发性硬化中的比较

Brain
IF11.7
2025-08-040
PRE
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

基于真实世界常规临床数据的个性化联邦学习在预测多发性硬化致残进展中的应用

2025-07-240
OAAI
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis

复发缓解型多发性硬化中与复发活动无关的进展标准化定义(PIRA)

2025-06-010
PRE
Explainable time-to-progression predictions in multiple sclerosis

多发性硬化症可解释的进展时间预测

2025-05-010
PRE
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study

血清阴性NMOSD的进展独立于复发活动和复发相关的恶化:一项国际队列研究

2025-04-140
OA
Pediatric, adult, and late onset multiple sclerosis: Cognitive phenotypes and gray matter atrophy

小儿,成人和迟发性多发性硬化症: 认知表型和灰质萎缩

2025-01-240
OA